Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
follistatin mRNA-loaded lipid nanoparticles
- Development stage
- Preclinical
- Lead developer
- Oregon State University
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intraperitoneal
01
Overview
Follistatin mRNA-loaded lipid nanoparticles are an experimental mRNA-based therapeutic designed to treat metastatic ovarian cancer and its associated cachexia. The therapy utilizes lipid nanoparticles (LNPs) to deliver mRNA encoding follistatin (FST), a natural antagonist of Activin A (ActA). Activin A is often overexpressed in gynecological and other cancers, where it promotes tumor growth, metastasis, and muscle atrophy. By inducing transient expression of FST, the LNPs inhibit ActA activity, leading to reduced tumor progression, decreased malignant ascites, and reversal of muscle wasting. Preclinical studies in murine models conducted by researchers at Oregon Health & Science University have shown that this therapy, particularly when combined with cisplatin, significantly extends survival and improves muscle mass.
- Other names
- Fst mRNA LNPsfollistatin mRNA LNPsFst mRNA-loaded LNPs
02
Targets
INHBB (Activin B)GDF8 (Myostatin)NODAL (Nodal growth differentiation factor)Activin A
Beyond the preview
Go deeper on follistatin mRNA-loaded lipid nanoparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on follistatin mRNA-loaded lipid nanoparticles.